Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology/Oncology, University of Chicago 2007 - 2010
  • Internal Medicine, University of Chicago 2004 - 2007
  • M.D., University of North Carolina at Chapel Hill 2004
• 

  Duke Appointment History

  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2018
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2013
  • Instructor Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2010
• Research
• 

  Selected Grants

  • MK-3475-587-00 awarded by Merck Sharp & Dohme 2019 - 2023
  • ECHO-208 awarded by Incyte Corporation 2018 - 2023
  • (BMS Adjuvant-915) awarded by Bristol-Myers Squibb Company 2017 - 2022
  • Immunocore awarded by Immunocore Limited 2017 - 2022
  • DV3-MEL-01 awarded by Dynavax Technologies Corporation 2017 - 2022
  • IMCgp100-201 awarded by Immunocore Limited 2016 - 2021
  • Optimize BMS CA209-357 awarded by Bristol-Myers Squibb Company 2016 - 2021
  • Celldex CDX011-05 awarded by Celldex Therapeutics, Inc. 2015 - 2020
  • BMS CA209-238-0025 awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2015 - 2020
  • CA209204 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by awarded by Bristol-Myers Squibb Company 2015 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • Collaborative Success: Expanding Options for Patients with Melanoma awarded by National Institutes of Health 1997 - 2019
  • An open label, multicenter, dose-escalation, phase 1B/2 study of the safety, efficacy, pharmacodynamics, and pharmacokin awarded by Reata Pharmaceuticals, Inc. 2014 - 2019
  • A phase Ii trial of Neoadjuvant Ipilimumab follwed by Melphalan (L-PAM) via isolated Limb infusion (ILI) for patients wi awarded by Bristol-Myers Squibb Company 2014 - 2018
  • Expanded access of MK-3475 in metastatic melanoma patients with limited to no treatment options awarded by Merck Sharp & Dohme 2014 - 2015
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Leaf, RK, Ferreri, C, Rangachari, D, Mier, J, Witteles, W, Ansstas, G, Anagnostou, T, Zubiri, L, Piotrowska, Z, Oo, TH, Iberri, D, Yarchoan, M, Salama, AKS, Johnson, DB, Leavitt, AD, Rahma, OE, Reynolds, KL, and Leaf, DE. "Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors." American Journal of Hematology 94, no. 5 (May 2019): 563-574.  Full Text
    • Coit, DG, Thompson, JA, Albertini, MR, Barker, C, Carson, WE, Contreras, C, Daniels, GA, DiMaio, D, Fields, RC, Fleming, MD, Freeman, M, Galan, A, Gastman, B, Guild, V, Johnson, D, Joseph, RW, Lange, JR, Nath, S, Olszanski, AJ, Ott, P, Gupta, AP, Ross, MI, Salama, AK, Skitzki, J, Sosman, J, Swetter, SM, Tanabe, KK, Wuthrick, E, McMillian, NR, and Engh, AM. "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 17, no. 4 (April 2019): 367-402.  Full Text
    • Ott, PA, Pavlick, AC, Johnson, DB, Hart, LL, Infante, JR, Luke, JJ, Lutzky, J, Rothschild, NE, Spitler, LE, Cowey, CL, Alizadeh, AR, Salama, AK, He, Y, Hawthorne, TR, Bagley, RG, Zhang, J, Turner, CD, and Hamid, O. "A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma." Cancer 125, no. 7 (April 2019): 1113-1123.  Full Text
    • Puza, CJ, Bressler, ES, Terando, AM, Howard, JH, Brown, MC, Hanks, B, Salama, AKS, and Beasley, GM. "The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy." The Journal of Surgical Research 236 (April 2019): 209-215.  Full Text
    • Kwak, M, Farrow, NE, Salama, AKS, Mosca, PJ, Hanks, BA, Slingluff, CL, and Beasley, GM. "Updates in adjuvant systemic therapy for melanoma." Journal of Surgical Oncology 119, no. 2 (January 2019): 222-231. (Review)  Full Text
    • Grant, MJ, DeVito, N, and Salama, AKS. "Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations." Melanoma Management 5, no. 4 (December 2018): MMT10-null. (Review)  Full Text
    • Tan, I, Malinzak, M, and Salama, AKS. "Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy." Journal for Immunotherapy of Cancer 6, no. 1 (July 31, 2018): 77-null.  Full Text
    • Barker, CA, and Salama, AK. "New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma." Journal of the National Comprehensive Cancer Network : Jnccn 16, no. 5S (May 2018): 646-650.  Full Text
    • Maio, M, Lewis, K, Demidov, L, Mandalà, M, Bondarenko, I, Ascierto, PA, Herbert, C, Mackiewicz, A, Rutkowski, P, Guminski, A, Goodman, GR, Simmons, B, Ye, C, Yan, Y, Schadendorf, D, and BRIM8 Investigators, . "Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial." The Lancet. Oncology 19, no. 4 (April 2018): 510-520.  Full Text
    • Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.  Full Text
    • Bhatti, MT, and Salama, AKS. "Neuro-ophthalmic side effects of molecularly targeted cancer drugs." Eye (London, England) 32, no. 2 (February 2018): 287-301. (Review)  Full Text
    • Gangadhar, TC, Hwu, W-J, Postow, MA, Hamid, O, Daud, A, Dronca, R, Joseph, R, O'Day, SJ, Hodi, FS, Pavlick, AC, Kluger, H, Oxborough, RP, Yang, A, Gazdoiu, M, Kush, DA, Ebbinghaus, S, and Salama, AKS. "Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program." Journal of Immunotherapy (Hagerstown, Md. : 1997) 40, no. 9 (November 2017): 334-340.  Full Text
    • Hamid, O, Puzanov, I, Dummer, R, Schachter, J, Daud, A, Schadendorf, D, Blank, C, Cranmer, LD, Robert, C, Pavlick, AC, Gonzalez, R, Hodi, FS, Ascierto, PA, Salama, AKS, Margolin, KA, Gangadhar, TC, Wei, Z, Ebbinghaus, S, Ibrahim, N, and Ribas, A. "Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma." European Journal of Cancer (Oxford, England : 1990) 86 (November 2017): 37-45.  Full Text
    • Rossfeld, K, Hade, EM, Gangi, A, Perez, M, Kinsey, EN, Grabska, J, Ederle, A, Zager, J, Salama, AK, Olencki, TE, and Beasley, GM. "Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics." International Journal of Surgery. Oncology 2, no. 9 (October 10, 2017): e43-null.  Full Text
    • Beasley, GM, Hu, Y, Youngwirth, L, Scheri, RP, Salama, AK, Rossfeld, K, Gardezi, S, Agnese, DM, Howard, JH, Tyler, DS, Slingluff, CL, and Terando, AM. "Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study." Annals of Surgical Oncology 24, no. 9 (September 2017): 2728-2733.  Full Text
    • Turner, MC, Rossfeld, K, Salama, AKS, Tyler, D, and Beasley, G. "Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?." Expert Opinion on Pharmacotherapy 18, no. 5 (April 2017): 487-495. (Review)  Full Text
    • Force, J, and Salama, AK. "First-line treatment of metastatic melanoma: role of nivolumab." ImmunoTargets and therapy 6 (January 2017): 1-10. (Review)  Full Text  Open Access Copy
    • Kinsey, EN, and Salama, AKS. "Metastatic uveal melanoma-A review of current therapies and future directions." European Oncology and Haematology 13, no. 2 (January 1, 2017): 100-106. (Review)  Full Text
    • Salama, AK. "Comparison between ketamine and hyoscine for the management of postoperative catheter-related bladder discomfort: A randomized controlled double-blind study." Journal of anaesthesiology, clinical pharmacology 33, no. 1 (January 2017): 76-80.  Full Text
    • Salama, AKS, and Moschos, SJ. "Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies." Annals of Oncology : Official Journal of the European Society for Medical Oncology 28, no. 1 (January 2017): 57-74. (Review)  Full Text
    • Hodi, FS, Chesney, J, Pavlick, AC, Robert, C, Grossmann, KF, McDermott, DF, Linette, GP, Meyer, N, Giguere, JK, Agarwala, SS, Shaheen, M, Ernstoff, MS, Minor, DR, Salama, AK, Taylor, MH, Ott, PA, Horak, C, Gagnier, P, Jiang, J, Wolchok, JD, and Postow, MA. "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial." The Lancet. Oncology 17, no. 11 (November 2016): 1558-1568.  Full Text
    • Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, JM, Hille, D, Ebbinghaus, S, Kang, SP, Zhou, W, and Ribas, A. "Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma." European Journal of Cancer (Oxford, England : 1990) 67 (November 2016): 46-54.  Full Text
    • Shoushtari, AN, Munhoz, RR, Kuk, D, Ott, PA, Johnson, DB, Tsai, KK, Rapisuwon, S, Eroglu, Z, Sullivan, RJ, Luke, JJ, Gangadhar, TC, Salama, AKS, Clark, V, Burias, C, Puzanov, I, Atkins, MB, Algazi, AP, Ribas, A, Wolchok, JD, and Postow, MA. "The efficacy of anti-PD-1 agents in acral and mucosal melanoma." Cancer 122, no. 21 (November 2016): 3354-3362.  Full Text
    • Salama, AKS, and Moschos, SJ. "Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies." Annals of oncology : official journal of the European Society for Medical Oncology (October 13, 2016).
    • Choe, JH, Andonian, BJ, Kim, GJ, and Salama, AK. "Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab." Immunotherapy 8, no. 10 (October 2016): 1163-1167.  Full Text
    • Sammons, S, Brady, D, Vahdat, L, and Salama, AK. "Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma." Melanoma Management 3, no. 3 (September 2, 2016): 207-216. (Review)  Full Text
    • Olson, AC, Thomas, S, Qin, R, Singh, B, Salama, JK, Kirkpatrick, J, and Salama, AK. "Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab." Melanoma Management 3, no. 3 (September 2016): 177-186.  Full Text
    • Qin, R, Olson, A, Singh, B, Thomas, S, Wolf, S, Bhavsar, NA, Hanks, BA, Salama, JK, and Salama, AKS. "Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab." International Journal of Radiation Oncology, Biology, Physics 96, no. 1 (September 2016): 72-77.  Full Text
    • Coit, DG, Thompson, JA, Algazi, A, Andtbacka, R, Bichakjian, CK, Carson, WE, Daniels, GA, DiMaio, D, Fields, RC, Fleming, MD, Gastman, B, Gonzalez, R, Guild, V, Johnson, D, Joseph, RW, Lange, JR, Martini, MC, Materin, MA, Olszanski, AJ, Ott, P, Gupta, AP, Ross, MI, Salama, AK, Skitzki, J, Swetter, SM, Tanabe, KK, Torres-Roca, JF, Trisal, V, Urist, MM, McMillian, N, and Engh, A. "NCCN Guidelines Insights: Melanoma, Version 3.2016." Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 8 (August 2016): 945-958.  Full Text
    • Farber, SH, Tsvankin, V, Narloch, JL, Kim, GJ, Salama, AKS, Vlahovic, G, Blackwell, KL, Kirkpatrick, JP, and Fecci, PE. "Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology 5, no. 7 (July 2016): e1172153-null. (Review)  Full Text
    • Salama, AKS, Postow, MA, and Salama, JK. "Irradiation and immunotherapy: From concept to the clinic." Cancer 122, no. 11 (June 2016): 1659-1671. (Review)  Full Text
    • Brys, AK, Bhatti, L, Bashir, MR, Jaffe, TA, Beasley, GM, Nath, NS, Salama, AKS, Tyler, DS, and Mosca, PJ. "Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma." Annals of surgical oncology 23, no. 4 (April 2016): 1090-1095.  Full Text
    • Coit, DG, Thompson, JA, Algazi, A, Andtbacka, R, Bichakjian, CK, Carson, WE, Daniels, GA, DiMaio, D, Ernstoff, M, Fields, RC, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Joseph, RW, Lange, JR, Martini, MC, Materin, MA, Olszanski, AJ, Ross, MI, Salama, AK, Skitzki, J, Sosman, J, Swetter, SM, Tanabe, KK, Torres-Roca, JF, Trisal, V, Urist, MM, McMillian, N, and Engh, A. "Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 4 (April 2016): 450-473.  Full Text
    • Barina, AR, Bashir, MR, Howard, BA, Hanks, BA, Salama, AK, and Jaffe, TA. "Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis." Abdominal Radiology (New York) 41, no. 2 (February 2016): 207-214.  Full Text
    • Singh, BP, and Salama, AKS. "Updates in Therapy for Advanced Melanoma." Cancers 8, no. 1 (January 15, 2016). (Review)  Full Text
    • Amin, A, Lawson, DH, Salama, AKS, Koon, HB, Guthrie, T, Thomas, SS, O'Day, SJ, Shaheen, MF, Zhang, B, Francis, S, and Hodi, FS. "Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma." Journal for Immunotherapy of Cancer 4 (January 2016): 44-null.  Full Text
    • Kinsey, EN, DeVito, N, Barrow, W, Myers, SA, and Salama, AKS. "Paraneoplastic Production of Granulocyte-macrophage Colony-stimulating Factor and Granulocyte Colony-stimulating Factor in a Case of Rapidly Progressing Cutaneous Squamous Cell Carcinoma." Clinical Skin Cancer 1, no. 1 (January 2016): 20-22.  Full Text
    • Lovly, CM, Salama, AKS, and Salgia, R. "Tumor Heterogeneity and Therapeutic Resistance." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 35 (January 2016): e585-e593. (Review)  Full Text
    • Lowe, JR, Perry, DJ, Salama, AKS, Mathews, CE, Moss, LG, and Hanks, BA. "Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy." Journal for Immunotherapy of Cancer 4 (January 2016): 89-null.  Full Text  Open Access Copy
    • Romain, PES, Salama, AKS, Lynn Ferguson, N, and Burbridge, RA. "Ipilimumab-Associated lymphocytic colitis: A case report." Translational Gastroenterology and Hepatology 5, no. 1 (January 1, 2016): 44-46.  Full Text
    • Salama, AK, Osman, KA, and Gouda, NA-R. "Remediation of lead and cadmium-contaminated soils." International journal of phytoremediation 18, no. 4 (January 2016): 364-367.  Full Text
    • Salama, AK, and Ali, HM. "Comparative study of hyoscine doses as antisialagogue for patients receiving ketofol sedation undergoing colonoscopy procedures." Anesthesia, essays and researches 10, no. 1 (January 2016): 94-97.  Full Text
    • Howie, LJ, Tyler, DS, and Salama, AKS. "Neoadjuvant use of ipilimumab in locally advanced melanoma." Journal of Surgical Oncology 112, no. 8 (December 2015): 841-843.  Full Text
    • Qin, R, and Salama, AK. "Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus." Melanoma Management 2, no. 4 (November 24, 2015): 311-314.  Full Text
    • Salama, AK. "Assessment of metals in cosmetics commonly used in Saudi Arabia." Environmental monitoring and assessment 188, no. 10 (October 2015): 553-.  Full Text
    • Ribas, A, Puzanov, I, Dummer, R, Schadendorf, D, Hamid, O, Robert, C, Hodi, FS, Schachter, J, Pavlick, AC, Lewis, KD, Cranmer, LD, Blank, CU, O'Day, SJ, Ascierto, PA, Salama, AKS, Margolin, KA, Loquai, C, Eigentler, TK, Gangadhar, TC, Carlino, MS, Agarwala, SS, Moschos, SJ, Sosman, JA, Goldinger, SM, Shapira-Frommer, R, Gonzalez, R, Kirkwood, JM, Wolchok, JD, Eggermont, A, Li, XN, Zhou, W, Zernhelt, AM, Lis, J, Ebbinghaus, S, Kang, SP, and Daud, A. "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial." The Lancet. Oncology 16, no. 8 (August 2015): 908-918.  Full Text
    • Postow, MA, Chesney, J, Pavlick, AC, Robert, C, Grossmann, K, McDermott, D, Linette, GP, Meyer, N, Giguere, JK, Agarwala, SS, Shaheen, M, Ernstoff, MS, Minor, D, Salama, AK, Taylor, M, Ott, PA, Rollin, LM, Horak, C, Gagnier, P, Wolchok, JD, and Hodi, FS. "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma." The New England Journal of Medicine 372, no. 21 (May 2015): 2006-2017.  Full Text
    • Bostwick, AD, Salama, AK, and Hanks, BA. "Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis." Journal for Immunotherapy of Cancer 3 (January 2015): 19-null.  Full Text  Open Access Copy
    • Dummer, R, Daud, A, Puzanov, I, Hamid, O, Schadendorf, D, Robert, C, Schachter, J, Pavlick, A, Gonzalez, R, Hodi, F, Cranmer, LD, Blank, C, O’Day, SJ, Ascierto, PA, Salama, AKS, Li, NX, Zhou, W, Lis, J, Ebbinghaus, S, Kang, PS, and Ribas, A. "A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma." Journal of Translational Medicine 13, no. Suppl 1 (2015): O5-O5.  Full Text
    • Gangadhar, TC, and Salama, AK. "Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types." Oncotargets and Therapy 8 (January 2015): 929-937. (Review)  Full Text
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of Surgical Oncology 21, no. 8 (August 2014): 2525-2531.  Full Text
    • Coit, DG, Thompson, JA, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daniels, GA, Daud, A, Dimaio, D, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Martini, MC, Olszanski, AJ, Ross, MI, Salama, A, Swetter, SM, Tanabe, KK, Trisal, V, Urist, MM, McMillian, NR, Ho, M, and National Comprehensive Cancer Network, . "Melanoma, version 4.2014." Journal of the National Comprehensive Cancer Network : Jnccn 12, no. 5 (May 2014): 621-629.  Full Text
    • Beasley, GM, Speicher, P, Sharma, K, Seigler, H, Salama, A, Mosca, P, and Tyler, DS. "Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma." Journal of the American College of Surgeons 218, no. 4 (April 2014): 686-692.  Full Text
    • Beasley, GM, Speicher, P, Sharma, K, Seigler, H, Salama, A, Mosca, P, and Tyler, DS. "Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma." Journal of the American College of Surgeons 218, no. 4 (January 1, 2014): 686-692.  Full Text
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of Surgical Oncology 21, no. 8 (January 1, 2014): 2525-2531.  Full Text
    • Salama, AKS, and Kim, KB. "MEK inhibition in the treatment of advanced melanoma." Current Oncology Reports 15, no. 5 (October 2013): 473-482. (Review)  Full Text
    • Salama, AKS, and Flaherty, KT. "BRAF in Melanoma: Current Strategies and Future Directions." CLINICAL CANCER RESEARCH 19, no. 16 (August 15, 2013): 4326-4334.  Full Text  Link to Item
    • Salama, AKS, and Kim, KB. "Trametinib (GSK1120212) in the treatment of melanoma." Expert Opinion on Pharmacotherapy 14, no. 5 (April 2013): 619-627. (Review)  Full Text
    • Shetty, G, Beasley, GM, Sparks, S, Barfield, M, Masoud, M, Mosca, PJ, Pruitt, SK, Salama, AKS, Chan, C, Tyler, DS, and Weinhold, KJ. "Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion." Ann Surg Oncol 20, no. 4 (April 2013): 1128-1135.  Full Text  Link to Item
    • Salama, AKS, and Kim, KB. "MEK inhibition in the treatment of advanced melanoma." Current Oncology Reports 15, no. 5 (2013): 473-482.  Full Text
    • Salama, AKS, de Rosa, N, Scheri, RP, Pruitt, SK, Herndon, JE, Marcello, J, Tyler, DS, and Abernethy, AP. "Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy." PLoS One 8, no. 3 (2013): e57665-.  Full Text  Open Access Copy  Link to Item
    • Salama, AKS. "Evolving pharmacotherapies for the treatment of metastatic melanoma." Clinical Medicine Insights. Oncology 7 (January 2013): 137-149.  Full Text
    • Gajewski, TF, Salama, AKS, Niedzwiecki, D, Johnson, J, Linette, G, Bucher, C, Blaskovich, MA, Sebti, SM, Haluska, F, and Canc, LGB. "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)." JOURNAL OF TRANSLATIONAL MEDICINE 10 (December 10, 2012).  Full Text  Link to Item
    • Salama, AKS, Rosa, ND, Scheri, RP, Herndon, JE, Tyler, DS, Marcello, J, Pruitt, SK, and Abernethy, AP. "The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost." Cancer Invest 30, no. 9 (November 2012): 637-641.  Full Text  Link to Item
    • Beasley, GM, Parsons, C, Broadwater, G, Selim, MA, Marzban, S, Abernethy, AP, Salama, AKS, Eikman, EA, Wong, T, Zager, JS, and Tyler, DS. "A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma." Annals of Surgery 256, no. 2 (August 2012): 350-356.  Full Text
    • Salgia, R, Hensing, T, Campbell, N, Salama, AK, Maitland, M, Hoffman, P, Villaflor, V, and Vokes, EE. "Personalized treatment of lung cancer." Seminars in Oncology 38, no. 2 (April 2011): 274-283. (Review)  Full Text
    • Surati, M, Robinson, M, Nandi, S, Faoro, L, Demchuk, C, Rolle, CE, Kanteti, R, Ferguson, BD, Hasina, R, Gangadhar, TC, Salama, AK, Arif, Q, Kirchner, C, Mendonca, E, Campbell, N, Limvorasak, S, Villaflor, V, Hensing, TA, Krausz, T, Vokes, EE, Husain, AN, Ferguson, MK, Karrison, TG, and Salgia, R. "Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database." Journal of clinical bioinformatics 1, no. 8 (February 2011): 1-11.  Full Text
    • El-Gendy, KS, Aly, NM, Mosallam, EM, and Salama, AK. "Preparation of antibodies and development of an enzyme immunoassay for determination of atrazine in environmental samples." Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 46, no. 4 (January 2011): 321-327.  Full Text
    • Mollberg, N, Surati, M, Demchuk, C, Fathi, R, Salama, AK, Husain, AN, Hensing, T, and Salgia, R. "Mind-mapping for lung cancer: Towards a personalized therapeutics approach." Advances in Therapy 28, no. 3 (2011): 173-194.  Full Text
    • Salama, AKS, and Hodi, FS. "Cytotoxic T-lymphocyte-associated antigen-4." Clinical Cancer Research 17, no. 14 (2011): 4622-4628.  Full Text
    • Tretiakova, M, Salama, AKS, Karrison, T, Ferguson, MK, Husain, AN, Vokes, EE, and Salgia, R. "MET and phosphorylated MET as potential biomarkers in lung cancer." Journal of Environmental Pathology, Toxicology and Oncology 30, no. 4 (2011): 341-354.
    • Radwan, MA, and Salama, AK. "Market basket survey for some heavy metals in Egyptian fruits and vegetables." Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association 44, no. 8 (August 2006): 1273-1278.  Full Text

  • Book Sections

    • Sammons, S, McNamara, M, Salama, AKS, and Crawford, J. "Immune checkpoint inhibition." In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315-353. June 27, 2018.  Full Text

  • Conference Papers

    • Owonikoko, TK, Papadopoulos, KP, Johnson, ML, Gil Martin, M, Moreno, V, Salama, AKS, Calvo, E, Yee, NS, Safran, H, González-Martín, A, Aljumaily, R, Mahadevan, D, Niu, J, Mohan, KK, Li, J, Stankevich, E, Lowy, I, Fury, MG, and Babiker, HM. "Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data." : American Society of Clinical Oncology (ASCO), May 20, 2018.  Full Text
    • Theivanthiran, B, DeVito, NC, Evans, K, Zhao, F, Xiao, C, Goldschmidt, BS, Edgar, R, Holtzhausen, AH, Salama, AKS, Lewicki, J, Strickler, JH, Viator, JA, and Hanks, BA. "A HSP-TLR-Wnt5a paracrine signaling axis drives CXCR2 ligand recruitment of myeloid-derived suppressor cells and represents a novel adaptive resistance mechanism to anti-PD-1 antibody therapy." : BMC, November 7, 2017.  Link to Item
    • Gajewski, TF, Niedzwiecki, D, Johnson, J, Linette, G, Bucher, C, Blaskovich, M, Sebti, S, and Haluska, F. "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104." June 20, 2006.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.